bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: A historical cohort study

World Journal of Surgical Oncology

Volumn 6, Issue , 2008, Pages

  Espíndola, Marília B ^a,b   Corleta, Oly C ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; INTERFERON; MELPHALAN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; TAMOXIFEN; VERAPAMIL; TUMOR MARKER;

ADOLESCENT; ADRENAL METASTASIS; ADULT; AGE; AGED; ARTICLE; BREAST METASTASIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DRUG RESPONSE; FEMALE; GENDER; HISTORICAL RESEARCH; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; SKIN METASTASIS; SKIN SURGERY; SURVIVAL TIME; UNIVARIATE ANALYSIS; VISCERAL METASTASIS; CANCER INVASION; ENZYME IMMUNOASSAY; LYMPH NODE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN TUMOR; SURVIVAL RATE;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 48249085741     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-6-65     Document Type: Article

References (41)

1. Markowitz JS Cosimi LA Carey RW Kang S Padyk C Sober AJ Cosimi AB Prognosis after initial recurrence of cutaneous melanoma Arch Surg 1991, 126:703-708. 2039357
2. Gilchrest BA Eller MS Geller AC Yaar M The pathogenesis of melanoma induced by ultraviolet radiation NEJM 1999, 340:1341-1348. 10.1056/ NEJM199904293401707 10219070
3. Stadelmann WK Rapaport DP Soong S-J Reintgen DS Buzaid AC Balch CM Prognostic Clinical pathologic features Cutaneous melanoma St. Louis, Missouri: Quality Medical Publishing, Inc Balch CM, Houghton AN, Sober AJ, Soong S-J 3 1998, 11-35.
4. Rünger TM Emmert S Schadendorf D Diem C Epe B Hllfritsch D Alterations of repair in melanoma cell lines resistant to Cisplatin, Fotemustine, or Etoposide J Invest Dermatol 2000, 114:34-39. 10.1046/ j.1523-1747.2000.00844.x 10620112
5. Jansen B Schlagbauer-Wadl H Brown BD Bryan RN van Elsas A Müller M Wollf K Eichler HG Pehamberger H bcl-2 antisense therapy chemosensitizes human melanoma in SCDI mice Nat Med 1998, 4:232-234. 10.1038/nm0298-232 9461199
6. Miller LJ Marx J Apoptosis [editorial] Science 1998, 281:1301. 10.1126/ science.281.5381.1301
7. Meterissian SH Apoptosis: Its role in the progression of and chemotherapy for carcinoma J Am Col Surg 1997, 184:658-666.
8. Wong CW Lee A Shientag L Yu J Dong Y Kao G Al-Mehdi AB Bernhard EJ Mushel RJ Apoptosis: An early event in metastatic inefficiency Cancer Res 2001, 61:333-338. 11196183
9. Korsmeyer SJ Bcl-2 initiates a new category of oncogenes: Regulators of cell death Blood 1992, 80:879-886. 1498330
10. Reed JA Albino AP Update of diagnostic and prognostic markers in cutaneous malignant melanoma Dermatol Clin 1999, 17:631-643. 10.1016/ S0733-8635(05)70112-1 10410863
11. Grover R Wilson GD Bcl-2 expression in malignant melanoma and its prognostic significance Eur J Surg Oncol 1996, 22:347-349. 10.1016/ S0748-7983(96)90176-6 8783649
12. Mikhail M Velasquez E Shapiro R Berman R Pavlik A Sorhaindo L Spira J Mir C Panageas KS Polsky D Osman I PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation Clin Cancer Res 2005, 11:5153-5157. 10.1158/1078-0432.CCR-05-0397 16033830
13. Tron VA Krajewski S Klein-Parker H Li G Ho VC Reed JC Immunohistochemical analysis of bcl-2 protein regulation in cutaneous melanoma Am J Pathol 1995, 146:643-650. 1869164 7534042
14. Tang L Tron VA Reed JC Mah KJ Krajewska M Li G Zhou X Ho VC Trotter MJ Expression of apoptosis regulators in cutaneous malignant melanoma Clin Cancer Res 1998, 4:1865-1871. 9717813
15. Leiter U Schmid RL Kaskel P Peter RA Krähn G Antiapoptotic bcl-2 and bclxL in advanced melanoma Arch Dermatol Res 2000, 292:225-232. 10.1007/s004030050479 10867810
16. Balch CB Buzaid AC Atking MB Cascinelli N Coit DG Fleming ID Houghton A Jr Kirkwood JM Mihm MF Morton DL Reintgen D Ross MI Sober A Soong S-J Thompson JA Thompson JF Gershenwald JE McMasters KM for the AJCC Melanoma Staging Committee A New American Joint Committee on Cancer staging system for cutaneous melanoma Cancer 2000, 88:1484-1491. 10.1002/ (SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D 10717634
17. Carson DA Ribeiro JM Apoptosis and disease Lancet 1993, 341:1251-1254. 10.1016/0140-6736(93)91154-E 8098400
18. Plettenberg A Ballaun C Pammer J Mildner M Strunk D Weninger W Tschachler E Human melanocytes and melanoma cells constitutively express the bcl-2 proto-oncogene in situ and in cell culture Am J Pathol 1995, 146:651-659. 1869182 7887447
19. Lu Q-L Abel P Foster C Lalani E-N bcl-2: Role in epithelial differentiation and oncogenesis Hum Pathol 1996, 27:102-110. 10.1016/ S0046-8177(96)90362-7 8617450
20. Takaoka A Adachi M Okuda H Sato S Yawata A Hinoda Y Takayama S Reed JC Imai K Anti-cell death activity promotes pulmonary metastasis of melanoma cells Oncogene 1997, 14:2971-2977. 10.1038/sj.onc.1201147 9205104
21. Drzewiecki KT Andersen K Survival with malignant melanoma - A regression analysis of prognostic factors Cancer 1982, 49:2414-2419. 10.1002/ 1097-0142(19820601)49:11<2414::AID-CNCR2820491132>3.0.CO;2-V 7074554
22. Gershenwald JE Sussman JJ Lee JE Melanoma The MD Anderson surgical oncology handbook Philadelphia: Lippincott Williams and Wilkins Feig BW, Berger DH, Fuhrman GM 2 1999, 38-68.
23. Barth A Wanek LA Morton CL Prognostic factors in 1,521 melanoma patients with distant metastases J Am Coll Surg 1995, 181:193-201. 7670677
24. Osborne JE Hutchinson PE Clinical correlates of Breslow thickness of malignant melanoma Br J Dermatol 2001, 144:476-483. 10.1046/ j.1365-2133.2001.04071.x 11260002
25. Fernandez-Pol JA Douglas MG Molecular interactions of cancer and age Hem/ Oncol Clin North Am 2000, 14:25-44.
26. Garbe C Blum A Epidemiology of cutaneous melanoma in Germany and worldwide [abstract] Skin Pharmacol Appl Skin Physiol 2001, 14:280-290. 10.1159/000056358 11586069
27. Ryan L Kramar A Borden E Prognostic factors in metastatic melanoma Cancer 1993, 71:2995-3005. 10.1002/ 1097-0142(19930515)71:10<2995::AID-CNCR2820711018>3.0.CO;2-P 8490827
28. Eberlein TJ Prognosis of patients with advanced melanoma J Am Coll Surg 1995, 181:263-265. 7670686
29. Presant CA Bartolucci AA Southeastern Cancer Study Group Prognostic factors in metastatic malignant melanoma - the southeastern cancer study group experience Cancer 1982, 49:2192-2196. 10.1002/ 1097-0142(19820515)49:10<2192::AID-CNCR2820491035>3.0.CO;2-R 6176309
30. Shaw HM McGovern VJ Milton GW Faraco GA McCarthy WH Histologic features of tumors and the female superiority in survival from malignant melanoma Cancer 1980, 45:1604-1608. 10.1002/ 1097-0142(19800401)45:7<1604::AID-CNCR2820450715>3.0.CO;2-O 7370919
31. Balch CM Soong SJ Gershenwald JE Thompson JF Reintgen DS Cascinelli N Urist M MacMasters KM Ross MI Kirkwood JM Atkins MB Thompson JA Coit DG Byrd D Desmond R Zhang Y Liu PY Lyman GH Morabito A Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 2001, 19:3622-3634. 11504744
32. Collins KA White WL Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma Am J Dermatopathol 1995, 17:429-438. 8599446
33. Morales-Ducret CRJ Rijn van de M LeBrun DP Smoller BR Bcl-2 expression in primary malignancies of the skin Arch Dermatol 1995, 131:909-912. 10.1001/archderm.131.8.909 7632062
34. O'Connor L Strasser A O'Reilly LA Hausmann G Adams JM Cory S Huang DC Bim: A novel member of the bcl-2 family that promotes apoptosis EMBO J 1998, 17:384-395. 1170389 9430630 10.1093/emboj/17.2.384
35. Kenny JJ Knobloch TJ Augustus M Carter KC Rosen CA Lang JC GRS, a novel member of the bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes Oncogene 1997, 14:997-1001. 10.1038/ sj.onc.1200898 9050999
36. Jansen B Wacheck V Heere-ress E Schlagbauer-Wadl H Hoeller C Lucas T Hoermann M Hollenstein U Wolff K Pehamberger H Chemosensitisation of malignant melanoma by BCL2 antisense therapy Lancet 2000, 356:1728-1733. 10.1016/S0140-6736(00)03207-4 11095261
37. Letai A Pharmacological manipulation of Bcl-2 family members to control cell death J Clin Invest 2005, 115:2648-2655. 1236690 16200198 10.1172/ JCI26250
38. Alvarez MG Besa PC Molecular basis of cancer and clinical applications Surg Clin North America 2000 80 443 457 10.1016/S0039-6109(05)70194-8
39. Wolter KG Verhaegen M Fernandez Y Nikolovska-Coleska Z Riblett M de la Vega CM Wang S Soengas MS Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins Cell Death Differ 2007, 14(9):1605-1616. 10.1038/sj.cdd.4402163 17541428
40. Tarhini AA Kirkwood JM Oblimersen in the treatment of metastatic melanoma Future Oncol 2007, 3:263-271. 10.2217/14796694.3.3.263 17547520
41. Mena S Benlloch M Ortega A Carretero J Obrador E Asensi M Petschen I Brown BD Estrela JM Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease Clin Cancer Res 2007, 9:2658-2666. 10.1158/1078-0432.CCR-06-2642